Unknown

Dataset Information

0

Vorinostat in the acute neuroinflammatory form of X-linked adrenoleukodystrophy.


ABSTRACT: OBJECTIVE:To identify a pharmacological compound targeting macrophages, the most affected immune cells in inflammatory X-linked adrenoleukodystrophy (cerebral X-ALD) caused by ABCD1 mutations and involved in the success of hematopoietic stem cell transplantation and gene therapy. METHODS:A comparative database analysis elucidated the epigenetic repressing mechanism of the related ABCD2 gene in macrophages and identified the histone deacetylase (HDAC) inhibitor Vorinostat as a compound to induce ABCD2 in these cells to compensate for ABCD1 deficiency. In these cells, we investigated ABCD2 and pro-inflammatory gene expression, restoration of defective peroxisomal ?-oxidation activity, accumulation of very long-chain fatty acids (VLCFAs) and their differentiation status. We investigated ABCD2 and pro-inflammatory gene expression, restoration of defective peroxisomal ß-oxidation activity, accumulation of very long-chain fatty acids (VLCFA) and differentiation status. Three advanced cerebral X-ALD patients received Vorinostat and CSF and MRI diagnostics was carried out in one patient after 80 days of treatment. RESULTS:Vorinostat improved the metabolic defects in X-ALD macrophages by stimulating ABCD2 expression, peroxisomal ß-oxidation, and ameliorating VLCFA accumulation. Vorinostat interfered with pro-inflammatory skewing of X-ALD macrophages by correcting IL12B expression and further reducing monocyte differentiation. Vorinostat normalized the albumin and immunoglobulin CSF-serum ratios, but not gadolinium enhancement upon 80 days of treatment. INTERPRETATION:The beneficial effects of HDAC inhibitors on macrophages in X-ALD and the improvement of the blood-CSF/blood-brain barrier are encouraging for future investigations. In contrast with Vorinostat, less toxic macrophage-specific HDAC inhibitors might improve also the clinical state of X-ALD patients with advanced inflammatory demyelination.

SUBMITTER: Zierfuss B 

PROVIDER: S-EPMC7261758 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Objective</h4>To identify a pharmacological compound targeting macrophages, the most affected immune cells in inflammatory X-linked adrenoleukodystrophy (cerebral X-ALD) caused by ABCD1 mutations and involved in the success of hematopoietic stem cell transplantation and gene therapy.<h4>Methods</h4>A comparative database analysis elucidated the epigenetic repressing mechanism of the related ABCD2 gene in macrophages and identified the histone deacetylase (HDAC) inhibitor Vorinostat as a comp  ...[more]

Similar Datasets

| S-EPMC10705002 | biostudies-literature
| S-EPMC3401223 | biostudies-literature
| S-EPMC3988840 | biostudies-literature
| S-EPMC4724231 | biostudies-literature
| S-EPMC8094714 | biostudies-literature
| S-EPMC10092852 | biostudies-literature
| S-EPMC4582021 | biostudies-literature
| S-EPMC6061697 | biostudies-literature
| S-EPMC7011349 | biostudies-literature
| S-EPMC8262477 | biostudies-literature